MORGAN STANLEY PLC/PUT/MERCK & CO./100/0.1/21.03.25 Stock

Warrant

DE000MB5C4N5

Real-time Bid/Ask 12:40:11 2024-06-21 pm EDT
0.157 EUR / 0.161 EUR +11.19% Intraday chart for MORGAN STANLEY PLC/PUT/MERCK & CO./100/0.1/21.03.25
Current month-25.91%
1 month-1.38%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-21 0.148 +3.50%
24-06-20 0.143 -2.72%
24-06-19 0.147 -2.65%
24-06-18 0.151 -0.66%
24-06-17 0.152 +2.01%

Delayed Quote Börse Stuttgart

Last update June 21, 2024 at 09:28 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying MERCK & CO., INC.
Issuer Morgan Stanley
WKN MB5C4N
ISINDE000MB5C4N5
Date issued 2023-04-05
Strike 100 $
Maturity 2025-03-21 (273 Days)
Parity 10 : 1
Emission price 1.02
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.98
Lowest since issue 0.115
Spread 0.004
Spread %2.48%

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
-
More about the company

Ratings for Merck & Co., Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Merck & Co., Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
129.7 USD
Average target price
142.7 USD
Spread / Average Target
+10.03%
Consensus